Fampridine · Ampyra / Fampyra

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Multiple Sclerosis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
EU
  • Improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7); conditional authorisation, switched to full authorisation on 2017-05-22
Product first approved 2011EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (16)
Multiple Sclerosis
NCT06136728 · MGH Institute of Health Professions
2024-09-20 – 2027-07 · Multiple Sclerosis
What this study did
NCT02219932 · Biogen
2014-09 – 2016-02 · Multiple Sclerosis
What this study did
NCT01328379 · Acorda Therapeutics
2011-03 – 2012-07 · Multiple Sclerosis
What this study did
NCT00654927 · Acorda Therapeutics
2003-11 – 2011-04 · Multiple Sclerosis
What this study did
Other / comorbidity
NCT07185347 · Assistance Publique - Hôpitaux de Paris
2025-10-21 – 2027-05-21 · Spinocerebellar Ataxia 27B (SCA27B)
What this study did
NCT03899584 · Coordinación de Investigación en Salud, Mexico
2019-07-17 – 2023-12 · Spinal Cord Injuries, Chronic
What this study did
NCT02422940 · Acorda Therapeutics
2015-04 – 2017-01 · Post-ischemic Stroke
What this study did
NCT02271217 · Acorda Therapeutics
2014-12 – 2016-10 · Post-Ischemic Stroke
What this study did
NCT00041717 · Acorda Therapeutics
2002-07 – 2004-05 · Spinal Cord Injury, Muscle Spasticity
What this study did
NCT01683838 · Acorda Therapeutics
2002-06 – 2004-02 · Spinal Cord Injury, Muscle Spasticity
What this study did
Phase 2/3 (6)
Multiple Sclerosis
NCT02006160 · State University of New York at Buffalo
2011-12 – 2016-02 · Multiple Sclerosis
What this study did
NCT01667497 · London Health Sciences Centre
2012-09 – 2015-08 · Cognitive Fatigue
What this study did
NCT01337986 · Washington University School of Medicine
2011-05 – 2013-12 · Multiple Sclerosis, Optic Neuritis
What this study did
Other / comorbidity
NCT03701581 · John Elfar
2021-06-05 – 2028-12 · Nerve Injury, Prostate Cancer
What this study did
NCT04026568 · Milton S. Hershey Medical Center
2021-08-17 – 2022-07-18 · Nerve Injury
What this study did
NCT01645787 · Columbia University
2012-06-01 – 2015-09 · Spinal Muscular Atrophy
What this study did
Phase 2 (19)
Multiple Sclerosis
NCT01576354 · University of Zurich
2012-03 – 2017-04 · Multiple Sclerosis
What this study did
NCT02280096 · Coordinación de Investigación en Salud, Mexico
2014-10 – 2017-02 · Multiple Sclerosis
What this study did
NCT01444300 · Oregon Health and Science University
2011-09 – 2013-09 · Multiple Sclerosis, Fatigue
What this study did
NCT01597297 · Biogen
2012-08 – 2013-08 · Multiple Sclerosis
What this study did
NCT00053417 · Acorda Therapeutics
2003-02 – 2003-12 · Multiple Sclerosis
What this study did
Other / comorbidity
NCT04516603 · Prof. Dominique de Quervain, MD
2040-01-01 – 2041-12-31 · Working Memory
What this study did
NCT06596434 · John Elfar
2026-01-01 – 2028-09 · Burns, Second Degree Burn, Wounds and Injuries
What this study did
NCT06003166 · University of Arizona
2025-04-21 – 2028-07-31 · Peripheral Nerve Injury, Crush Injury
What this study did
NCT06294821 · John Elfar
2026-11 – 2028-07 · Compression Neuropathy, Carpal Tunnel Syndrome
What this study did
NCT06333171 · John Elfar
2025-09 – 2028-03 · Wounds, Wound of Skin, Wound Heal, Wounds and Injuries
What this study did
NCT06751784 · University of Basel
2025-05-22 – 2027-03-31 · Working Memory, Mild to Moderate Depression
What this study did
NCT03578354 · Massachusetts Eye and Ear Infirmary
2019-01 – 2024-08 · Vestibular Migraine, Migraine Disorders, Vestibular Diseases
What this study did
NCT04652557 · Prof. Dominique de Quervain, MD
2021-11-01 – 2023-01-26 · Working Memory
What this study did
NCT01543750 · University of California, Los Angeles
— · Episodic Ataxia Type 2
What this study did
NCT03658408 · University of Rochester
2018-10-03 – 2018-10-30 · Prostate Disease
What this study did
NCT01621113 · Kessler Foundation
2012-06 – 2017-10-16 · Spinal Cord Injury
What this study did
NCT02166346 · Johns Hopkins University
2014-02 – 2017-01-08 · Transverse Myelitis, Neuromyelitis Optica, Idiopathic Transverse Myelitis, Myelitis NOS
What this study did
NCT02656160 · Brigham and Women's Hospital
2016-01 – 2016-07 · Sleep Apnea, Obstructive
What this study did
NCT00056810 · FDA Office of Orphan Products Development
2002-09 – 2005-05 · Guillain-Barre Syndrome
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT06853015 · Shirley Ryan AbilityLab
2025-02-01 – 2026-12-30 · SCI - Spinal Cord Injury
What this study did
NCT01491022 · University of Miami
2012-07 – 2014-07 · Parkinson's Disease
What this study did
Phase 1 (6)
Other / comorbidity
NCT07171203 · University of California, San Diego
2026-05-13 – 2031-07 · Gastrointestinal Stromal Tumors
What this study did
NCT07832331 · Milton S. Hershey Medical Center
2026-12-01 – 2027-12-01 · Vocal Cord Paralysis, Recurrent Laryngeal Nerve Palsy
What this study did
NCT05447676 · Shirley Ryan AbilityLab
2022-06-30 – 2025-06-30 · Spinal Cord Injury
What this study did
NCT02868567 · Hospital for Special Surgery, New York
2016-03 – 2025-05 · Motor Neuron Disease, Upper
What this study did
NCT04148781 · Courtney Casserly
2022-03-22 – 2024-01 · Optic Neuritis
What this study did
Phase 4 (9)
Multiple Sclerosis
NCT02849782 · Centre Hospitalier Universitaire de Besancon
2014-02-04 – 2019-03-01 · Multiple Sclerosis
What this study did
NCT02208050 · University College Dublin
2014-02-21 – 2016-02-16 · Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
What this study did
NCT02146534 · Clinique Neuro-Outaouais
2013-12 – 2016-01 · Multiple Sclerosis
What this study did
NCT02143167 · University of Southern Denmark
2014-05 – 2015-01 · Multiple Sclerosis
What this study did
NCT02259361 · Sheba Medical Center
2014-11 – 2014-11 · Multiple Sclerosis
What this study did
NCT01656148 · University of Southern Denmark
2012-06 – 2014-05 · Multiple Sclerosis
What this study did
NCT01356940 · Brown, Theodore R., M.D., MPH
2010-11 – 2013-04 · Multiple Sclerosis
What this study did
Other / comorbidity
NCT01975324 · Neuro-Ophthalmologic Associates, PC
2013-07 – 2015-12 · Non Arteritic Ischemic Optic Neuropathy
What this study did
Early phase / not applicable (5)
Multiple Sclerosis
NCT03847545 · University of Southern Denmark
2018-12-12 – 2021-10-15 · Multiple Sclerosis
What this study did
Other / comorbidity
NCT07922122 · TryAbility LLC
2026-06-06 – 2027-09-08 · Spinal Cord Injuries
What this study did
NCT07532460 · Boris Quednow
2026-05-28 – 2027-08 · Cocaine Use Disorder (CUD), Cognitive Impairments
What this study did
NCT05274477 · Prof. Dominique de Quervain, MD
2022-06-28 – 2024-06-30 · Working Memory, Post-covid-19
What this study did
NCT01811706 · University of Florida
2013-02 – 2013-12 · Spinocerebellar Ataxias Type 1, Spinocerebellar Ataxias Type 2, Spinocerebellar Ataxias Type 3, Spinocerebellar Ataxias Type 6
What this study did

Competitive landscape

This drug's own stage for Multiple Sclerosis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Fampridine (Ampyra / Fampyra): this drugApprovedSmall moleculeVoltage-gated potassium channel (Kv), Voltage-gated potassium channels (Kv1/Shaker/KCNA family), Potassium Channel BlockerPartial signal
NCT00127530: Timed walk responders: fampridine 78/224 (35%) vs placebo 6/72 (8%), p<0.0001 (Goodman et al., Lancet 2009)
AlemtuzumabApprovedMonoclonal antibodyCD52Partial signal
NCT00930553: Annualized Relapse Rate (ARR) (Year 3, 4, 5, 6 from the Baseline (Month 0 of CAMMS323 and Month 0 of CAMMS324 for "Alemtuzumab Treatment CAMMS323 Extension" group and "Alemtuzumab Treatment CAMMS324 Extension" group, respectively)): Alemtuzumab Treatment CAMMS323 Extension — Year 3: 0.19 relapses per participant per year; Year 4: 0.16 relapses per participant per year; Year 5: 0.15 relapses per participant per year; Year 6: 0.12 relapses per participant per year | Alemtuzumab Treatment CAMMS324 Extension — Year 3: 0.22 relapses per participant per year; Year 4: 0.24 relapses per participant per year; Year 5: 0.19 relapses per participant per year; Year 6: 0.16 relapses per participant per year
NCT00548405: Percentage of Participants With Sustained Accumulation of Disability (SAD) (Up to 2 years): Alemtuzumab 12 mg 12.71% (95% CI 9.89 to 16.27) vs Interferon Beta-1a 21.13% (95% CI 15.95 to 27.68)
BafiertamApprovedSmall moleculeNrf2 pathway (fumaric acid ester)not yet gradedNo reviewed efficacy summary in this indication
Cladribine (MAVENCLAD®)ApprovedSmall moleculeAdenosine deaminase-resistant purine analog, DNA synthesis machinery in lymphocytesReliable signal
NCT00213135: Annualized Qualifying Relapse Rate (Week 96): Cladribine 5.25 mg/kg 0.15 relapses per year (95% CI 0.12 to 0.17) | Cladribine 3.5 mg/kg 0.14 relapses per year (95% CI 0.12 to 0.17) vs Placebo 0.33 relapses per year (95% CI 0.29 to 0.38)
CopaxoneApprovedPeptideMyelin basic protein-mimetic immunomodulationnot yet gradedNo reviewed efficacy summary in this indication
Dimethyl Fumarate (Tecfidera)ApprovedSmall moleculeNrf2 pathway (fumaric acid ester)Reliable signal
NCT00451451: Adjusted annualized relapse rate at 2 years: 0.224 relapses/year (95% CI 0.179–0.282) with BG00012 240 mg BID vs 0.401 (95% CI 0.329–0.488) with placebo; 0.198 (95% CI 0.156–0.252) with BG00012 240 mg TID vs 0.401 (95% CI 0.329–0.488) with placebo.
NCT00420212: Estimated proportion relapsed by 2 years: 27% with BG-12 240 mg twice daily and 26% with 240 mg three times daily vs 46% with placebo (P<0.001 for both comparisons) (DEFINE, N Engl J Med 2012).
Diroximel Fumarate (Vumerity)ApprovedSmall moleculeNrf2 pathway (fumaric acid ester)Weak signal
NCT03093324: Primary GI symptom days: mean 1.5 (SD 2.85) with ALKS 8700 vs 2.5 (SD 4.68) with dimethyl fumarate; rate ratio 0.542 (95% CI 0.390-0.754), p=0.0003.
Fingolimod (Gilenya)ApprovedSmall moleculeSphingosine 1-phosphate receptor (S1PR, specifically S1P1), S1P receptor, Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)Reliable signal
NCT00289978: Estimated Annualized Aggregate Relapse Rate (ARR) (Baseline to end of study (Month 24)): Fingolimod 1.25 mg 0.16 Relapses per year (95% CI 0.13 to 0.19) | Fingolimod 0.5 mg 0.18 Relapses per year (95% CI 0.15 to 0.22) vs Placebo 0.4 Relapses per year (95% CI 0.34 to 0.47)
NCT00340834: Annualized relapse rate over 12 months: fingolimod 1.25 mg 0.20 (95% CI 0.16 to 0.26) and 0.5 mg 0.16 (95% CI 0.12 to 0.21) vs interferon beta-1a IM 0.33 (95% CI 0.26 to 0.42); p<0.001 for both comparisons. n=1,292 randomized (TRANSFORMS, Cohen 2010, NEJM).
Interferon Beta-1a (Avonex)ApprovedBiologic (subtype unspecified)Type I Interferon receptor (IFNAR)Weak signal
NCT00211887: ARR - PDEs (Baseline to Month 36): IFN + GA 0.12 relapses per year | IFB-1a 0.16 relapses per year vs Glatiramer 0.11 relapses per year
Interferon Beta-1bApprovedBiologic (subtype unspecified)Interferon beta receptor (type I IFN signaling), Type I interferon receptorPartial signal
NCT00185211: Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS at Selected Points in Time (up to 60 months after start of treatment): Initial IFNB-1b (Interferon Beta-1b) — Kaplan-Meier estimate at year 2: 26.9 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 36.7 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 46.2 cum. percentage of particip. with CDMS vs Initial Placebo — Kaplan-Meier estimate at year 2: 45 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 51.2 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 57.3 cum. percentage of particip. with CDMS
NCT00099502: Enrolled 897 (250mcg) + 899 (500mcg) + 448 (glatiramer acetate) = 2244 patients (matches this trial's enrollment). Annualized relapse rate 0.33-0.36 across arms; no statistically significant difference in relapse/progression measures between the 500mcg and 250mcg IFN beta-1b doses, or vs glatiramer acetate. missed
Natalizumab (Tysabri)ApprovedMonoclonal antibodyα4 integrinReliable signal
NCT00027300: Sustained disability progression at 2 years reduced 42% (hazard ratio 0.58, 95% CI 0.43-0.77, P<0.001; cumulative probability 17% natalizumab vs 29% placebo); clinical relapse rate at 1 year reduced 68% (P<0.001).
NCT03689972: Part 1: Mean Number of New or Newly Enlarging T2 Hyperintense Lesions at Week 72 (Week 72): Part 1: IV Q4W 0.05 number of T2 lesions (95% CI 0.01 to 0.22) | Part 1: IV Q6W 0.2 number of T2 lesions (95% CI 0.07 to 0.63)
OcrelizumabApprovedMonoclonal antibodyCD20Partial signal
NCT05123703: Protocol-defined annualized relapse rate: ocrelizumab 0.070 vs fingolimod 0.135; adjusted rate ratio 0.517 (95% CI 0.193 to 1.329), non-inferiority analysis (CT.gov posted results); Roche states non-inferiority to fingolimod with a 48% lower relapse risk.
NCT01247324: Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks (Week 96): Interferon Beta-1a 44 mcg SC 0.292 relapses/participant year of treatment (95% CI 0.235 to 0.361) | Ocrelizumab 0.156 relapses/participant year of treatment (95% CI 0.122 to 0.2)
Ocrevus ZunovoApprovedMonoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
OfatumumabApprovedMonoclonal antibodyCD20Reliable signal
NCT02792231: Annualized Relapse Rate (ASCLEPIOS II): 0.10 (ofatumumab) vs 0.25 (teriflunomide); difference -0.15 (95% CI: -0.20, -0.09)
NCT02792218: Annualized relapse rate (median 1.6-year follow-up): 0.11 ofatumumab vs 0.22 teriflunomide; difference -0.11 (95% CI -0.16 to -0.06).
Ozanimod (Zeposia)ApprovedSmall moleculeS1P receptorPartial signal
NCT02047734: Adjusted annualized relapse rate (ARR) over 24 months (RADIANCE): 0.17 ozanimod 1.0mg, 0.22 ozanimod 0.5mg, vs 0.28 interferon beta-1a; rate ratio vs interferon 0.62 (p<0.0001) for the 1.0mg dose and 0.79 (p=0.0167) for the 0.5mg dose
NCT02294058: Adjusted Annualized Relapse Rate (ARR) During the Treatment Period (12 months): Ozanimod 0.5 mg 0.241 relapses/year (95% CI 0.188 to 0.308) | Ozanimod 1 mg 0.181 relapses/year (95% CI 0.14 to 0.236) vs Interferon Beta-1a 0.35 relapses/year (95% CI 0.279 to 0.44)
Peginterferon Beta-1a (Plegridy)ApprovedBiologic (subtype unspecified)Type I interferon receptor, Interferon beta receptor (type I IFN signaling)Reliable signal
NCT00906399: Annualized Relapse Rate (ARR) at 1 Year (1 Year): Year 1: Peginterferon Beta-1a Q4W 0.288 relapses per person-years (95% CI 0.234 to 0.355) | Year 1: Peginterferon Beta-1a Q2W 0.256 relapses per person-years (95% CI 0.206 to 0.318) vs Year 1: Placebo 0.397 relapses per person-years (95% CI 0.328 to 0.481)
NCT01939002: New or increased FLS during the first 8 weeks: 10.3% overall versus 25% null (p<0.0001); current FLS therapy 13% versus naproxen 7.4% (p=0.2037).
PonesimodApprovedSmall moleculeS1P receptorReliable signal
NCT02425644: Annualized relapse rate at week 108: 0.202 ponesimod vs 0.290 teriflunomide; rate ratio 0.695 (99% CI 0.536-0.902); 30.5% relative reduction; P<.001.
Rebif (interferon Beta 1a)ApprovedBiologic (subtype unspecified)Interferon beta receptor (type I IFN signaling), Type I interferon receptorWeak signalFeatured results are non-efficacy only in this race
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)Weak signalFeatured results are non-efficacy only in this race
Siponimod (Mayzent)ApprovedSmall moleculeS1P receptorWeak signal
NCT01665144: EXPAND (n=1,651), primary endpoint 3-month confirmed disability progression on EDSS: 26.3% with siponimod vs 31.7% with placebo; HR 0.79 (95% CI 0.65 to 0.95), Cox model p=0.0134 (CT.gov posted results).
Tascenso ODTApprovedSmall moleculeS1P receptornot yet gradedNo reviewed efficacy summary in this indication
Teriflunomide HMR1726 (Aubagio)ApprovedSmall moleculeDihydroorotate dehydrogenase (DHODH)Reliable signal
NCT03122652: Time to first clinical demyelinating event: unadjusted HR 0.37 (95% CI 0.16-0.84; P=.02), adjusted HR 0.28 (95% CI 0.11-0.71; P=.007), teriflunomide vs placebo (63% unadjusted / 72% adjusted risk reduction)
NCT00751881: Annualized relapse rate (core period): placebo 0.501, teriflunomide 7 mg 0.389 (relative reduction 22.3%, p=0.0183), 14 mg 0.319 (relative reduction 36.3%, p=0.0001); step-down testing, 14 mg first (CT.gov posted results).
Tyruko (natalizumab-Sztn)ApprovedMonoclonal antibodyα4 integrinnot yet gradedNo reviewed efficacy summary in this indication
Ublituximab (Briumvi)ApprovedMonoclonal antibodyCD20Reliable signal
NCT03277248: Annualized Relapse Rate (ARR) (Up to 96 weeks): Ublituximab + Oral Placebo 0.091 relapses per participant-years (95% CI 0.049 to 0.169) vs Teriflunomide + IV Placebo 0.178 relapses per participant-years (95% CI 0.109 to 0.291)
NCT03277261: Annualized Relapse Rate (ARR) (Up to 96 weeks): Ublituximab + Oral Placebo 0.076 relapses per participant-years (95% CI 0.042 to 0.138) | Teriflunomide + IV Placebo 0.188 relapses per participant-years (95% CI 0.124 to 0.283)
ABP 692Phase 3Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
BCD-281Phase 3Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
CT-P53Phase 3Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
Divozilimab (Ivlizi)Phase 3Monoclonal antibodyCD20Reliable signal
NCT05385744: Annualised relapse rate over 2 years (100 weeks): divozilimab 0.057 vs teriflunomide 0.164
FenebrutinibPhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
FrexalimabPhase 3Monoclonal antibodyCD40 ligand (CD40L / CD154)not yet gradedNo reviewed efficacy summary in this indication
Nabiximols (Sativex)Phase 3BotanicalCannabinoid CB1/CB2 receptors (agonist)Partial signal
NCT04657666: Change From Baseline in Lower Limb Muscle Tone-6 (LLMT-6) (Baseline (predose Day 1 of Treatment Period 1) up to Day 51 (end of treatment of Treatment Period 2)): Nabiximols -0.23 units on a scale (Standard Error 0.07) vs Placebo -0.26 units on a scale (Standard Error 0.07) missed
NCT01610700: Change From Baseline in Composite Primary Impairment Visual Analogue Scale Score at the End of 6 Weeks of Treatment (baseline and 6 weeks): GW-1000-02 -25.32 units on a scale (Standard Deviation 23.42) vs Placebo -19.32 units on a scale (Standard Deviation 27.02) missed
RemibrutinibPhase 3Small moleculeBruton's tyrosine kinase (BTK)not yet gradedNo reviewed efficacy summary in this indication
TolebrutinibPhase 3Small moleculeBruton's tyrosine kinase (BTK)Reliable signal
NCT04411641: HERCULES (n=1,131, nrSPMS), primary endpoint time to onset of 6-month confirmed disability progression on EDSS: tolebrutinib 60 mg vs placebo HR 0.693 (95% CI 0.546 to 0.880), Cox regression p=0.0026 (CT.gov posted results).
NCT04458051: 6-month composite confirmed disability progression (cCDP), tolebrutinib vs placebo: HR 1.01 (95% CI 0.81-1.26), p=.94 — no difference from placebo. missed
Vidofludimus CalciumPhase 3—Dihydroorotate dehydrogenase (DHODH)not yet gradedNo reviewed efficacy summary in this indication
CNM-Au8Phase 2/3Nanoparticlemitochondrial energy metabolismPartial signal
NCT04626921: LCLA (Best-Corrected Low-Contrast Letter Acuity) change across both eyes at Week 144 vs original randomization baseline, CNM-Au8 arm: least-squares mean difference +8.70 letters (SE 1.88), 95% CI 5.0 to 12.4, p<0.0001
CorubrutinibPhase 2Small moleculeBruton's tyrosine kinase (BTK)Partial signal
NCT05798520: Biogen reported that BIIB091 achieved proof-of-concept in relapsing-remitting MS (no figures released)
ForalumabPhase 2Monoclonal antibodyCD3not yet gradedNo reviewed efficacy summary in this indication
IrafamdastatPhase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
A-005
Phase 1(overall)
Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
AZD0120Phase 1Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
Azercabtagene Zapreleucel
Phase 1(overall)
Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
IDP-023Phase 1Cell therapyAllogeneic g-NK cell therapynot yet gradedNo reviewed efficacy summary in this indication
RG6035
—(overall)
Monoclonal antibody—not yet gradedNo reviewed efficacy summary in this indication
RG6182
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
BaminerceptDiscontinuedProtein / enzyme therapeuticLymphotoxin-beta receptor (LTβR)not yet gradedNo reviewed efficacy summary in this indication
Firategrast (SB-683699)DiscontinuedSmall moleculeVLA-4 (integrin alpha-4/beta-1), Integrin alpha-4 (ITGA4)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(12 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ampyra / Fampyra (Fampridine) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (10)
March 2027 (1)
Phase 2Working Memory, Mild to Moderate DepressionRecruiting
Est. primary completion 2027-03-31 · NCT06751784 · CT.gov ↗
What to watch
May 2027 (2)
Phase 3Multiple SclerosisRecruiting
Est. primary completion 2027-05 · NCT06136728 · CT.gov ↗
What to watch
Phase 3Spinocerebellar Ataxia 27B (SCA27B)Recruiting
Est. primary completion 2027-05-21 · NCT07185347 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2/3Nerve Injury, Prostate CancerRecruiting
Est. primary completion 2027-07 · NCT03701581 · CT.gov ↗
What to watch
Early phase / not applicableSpinal Cord InjuriesRecruiting
Est. primary completion 2027-07-08 · NCT07922122 · CT.gov ↗
What to watch
August 2027 (1)
Early phase / not applicableCocaine Use Disorder (CUD), Cognitive ImpairmentsRecruiting
Est. primary completion 2027-08 · NCT07532460 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Wounds, Wound of Skin, Wound Heal, Wounds and InjuriesRecruiting
Est. primary completion 2027-09 · NCT06333171 · CT.gov ↗
What to watch
December 2027 (3)
Phase 2Compression Neuropathy, Carpal Tunnel SyndromeNot yet recruiting
Est. primary completion 2027-12 · NCT06294821 · CT.gov ↗
What to watch
Phase 1Vocal Cord Paralysis, Recurrent Laryngeal Nerve PalsyNot yet recruiting
Est. primary completion 2027-12-01 · NCT07832331 · CT.gov ↗
What to watch
Phase 2Peripheral Nerve Injury, Crush InjuryRecruiting
Est. primary completion 2027-12-31 · NCT06003166 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
Phase 2Burns, Second Degree Burn, Wounds and InjuriesRecruiting
Est. primary completion 2028-06 · NCT06596434 · CT.gov ↗
What to watch
2030 (1)
July 2030 (1)
Phase 1Gastrointestinal Stromal TumorsRecruiting
Est. primary completion 2030-07 · NCT07171203 · CT.gov ↗
What to watch

See the full readout calendar ↗